|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Xenografts** | **Membrane Scoreb** | **Heterogeneous Expression** | **Dose (mg/Kg)** | **TVI (%)c** |
| HPAFII | 3+ | HO | 5 | 96 |
| AsPc-1 | 0 | nd | 5 | 0 |
| HCC-1806 | 1+ | HO | 3.5 | 92.7 |
| HCC-70 | 1+ | HO | 2.5 | 98 |
| SW780 | 2+ | HO | 5 | 97 |
| PC-PDX6Pa | 3+ | HO | 5 | 77.3 |
| PDX21a | 1+ | HO | 5 | 77.5 |
| PDX347a | 3+ | HO | 5 | 94.7 |
| PDX22a | 1+ | HO | 5 | 50 |
| CTG-1388a | 2+ | HE | 5 | 50 |
| CTG-1652a | 2+ | HE | 5 | 37.7 |

Supplementary Table S4

**Supplementary Table S4:** Antitumor activity of MEN1309/OBT076 on xenograft and PDX models with different CD205 antigen expression. a) PDX models.b) Score indicate the staining intensity. HE = heterogeneous. HO = homogeneous. c) TVI%, tumor volume inhibition, expressed as a percentage, indicates the ratio % between the mean of the tumor volume of the test article-treated group and the control treated with drug vehicle calculated at the Nadir of tumor growth.